Eliglustat(continued)
▶Eliglustatis predicted to increase the exposure totricyclic
antidepressants(nortriptyline). Adjust dose.oTheoretical
Elotuzumab→see monoclonal antibodies
Eltrombopag
▶Antacidsdecrease the absorption ofeltrombopag.Eltrombopag
should be taken 2 hours before or 4 hours afterantacids.
rStudy
▶Oralcalcium saltsdecrease the absorption ofeltrombopag.
Eltrombopagshould be taken 2 hours before or 4 hours after
calcium salts.rStudy
▶Dairy productsare predicted to decrease the absorption of
eltrombopag.Eltrombopagshould be taken 2 hours before or
4 hours afterdairy products.rTheoretical
▶Iron (oral)is predicted to decrease the absorption of
eltrombopag.Eltrombopagshould be taken 2 hours before or
4 hours afteriron (oral).rTheoretical
▶Seleniumis predicted to decrease the absorption of
eltrombopag.Eltrombopagshould be taken 2 hours before or
4 hours afterselenium.rTheoretical
▶Eltrombopagis predicted to increase the exposure tostatins.
Monitor and adjust dose.oStudy
▶Zincis predicted to decrease the absorption ofeltrombopag.
Eltrombopagshould be taken 2 hours before or 4 hours after
zinc.rTheoretical
Eluxadoline
▶Ciclosporinincreases the exposure toeluxadoline. Avoid.
oStudy
▶Fibrates(gemfibrozil)are predicted to increase the exposure to
eluxadoline. Avoid.oTheoretical
▶HIV-protease inhibitors(atazanavir, lopinavir, ritonavir,
saquinavir, tipranavir)are predicted to increase the exposure
toeluxadoline. Avoid.oTheoretical
▶Rifampicinis predicted to increase the exposure to
eluxadoline. Avoid.oTheoretical
▶Eluxadolineis predicted to increase the exposure tostatins.
oStudy
Elvitegravir
▶Antacidsmoderately decrease the exposure toelvitegravir.
Separate administration by at least 4 hours.oStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the
concentration ofelvitegravir. Avoid.rTheoretical
▶Bosentanis predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶Elvitegraviris predicted to decrease the anticoagulant effect of
coumarins.oTheoretical
▶Efavirenzis predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶Enzalutamideis predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶HIV-protease inhibitors(atazanavir, lopinavir)(boosted with
ritonavir) increase the concentration ofelvitegravir. Refer to
specialist literature.oStudy
▶Mitotaneis predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶Nevirapineis predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶Rifampicinis predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶St John’s Wortis predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
Empagliflozin→seeTABLE 14p. 850 (antidiabetic drugs),TABLE 8
p. 848 (hypotension)
Enalapril→see ACE inhibitors
Enoxaparin→see low molecular-weight heparins
Entacapone
▶Iron (oral)is predicted to decrease the absorption of
entacapone. Separate administration by at least 2 hours.
oTheoretical
▶Entacaponeincreases the exposure tolevodopa. Monitor side
effects and adjust dose.oStudy
▶Entacaponeis predicted to increase the exposure to
methyldopa.oTheoretical▶Entacaponeis predicted to increase the risk of elevated blood
pressure when given withmonoamine-oxidase A and B
inhibitors, irreversible. Avoid.rTheoretical
▶Entacaponeis predicted to increase the risk of cardiovascular
side-effects when given withsympathomimetics, inotropic.
oTheoretical
▶Entacaponeis predicted to increase the risk of cardiovascular
side-effects when given withsympathomimetics, vasoconstrictor
(adrenaline/epinephrine, noradrenaline/norepinephrine).
oStudy
Enteral feeds
▶Antacids(aluminium hydroxide)increase the risk of blocked
enteral or nasogastric tubes when given withenteral feeds.
oStudy
▶Enteral feedsdecrease the absorption ofantiepileptics
(phenytoin).rStudy
▶Enteral feeds(vitamin-K containing) potentially decrease the
anticoagulant effect ofcoumarins.rAnecdotal
▶Enteral feeds(vitamin-K containing) potentially decrease the
effects ofphenindione.rTheoretical
▶Enteral feedsdecrease the exposure toquinolones
(ciprofloxacin).oStudy
▶Sucralfateincreases the risk of blocked enteral or nasogastric
tubes when given withenteral feeds. Separate administration
by 1 hour.oStudy
▶Enteral feedsdecrease the exposure totheophylline.o
Study
Enzalutamide
GENERAL INFORMATIONCaution with concurrent
chemotherapy—safety and efficacy not established.
▶Enzalutamideis predicted to decrease the exposure to
abiraterone. Avoid.rTheoretical
▶Enzalutamideis predicted to decrease the exposure to
aldosterone antagonists(eplerenone). Avoid.oTheoretical
▶Enzalutamideis predicted to decrease the exposure to
alprazolam. Adjust dose.oTheoretical
▶Enzalutamideis predicted to decrease the exposure to
antiarrhythmics(disopyramide, dronedarone). Avoid.r
Study
▶Enzalutamideis predicted to decrease the efficacy of
antiarrhythmics(propafenone).oStudy
▶Enzalutamideis predicted to decrease the exposure to
anticholinesterases, centrally acting(donepezil).nStudy
▶Enzalutamideis predicted to slightly decrease the exposure to
antiepileptics(brivaracetam).oTheoretical
▶Enzalutamideis predicted to decrease the exposure to
antiepileptics(perampanel). Monitor and adjust dose.o
Study
▶Enzalutamideis predicted to decrease the exposure to
antifungals, azoles(isavuconazole). Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
antimalarials(artemether)(with lumafantrine). Avoid.r
Study
▶Enzalutamideis predicted to decrease the concentration of
antimalarials(piperaquine). Avoid.oTheoretical
▶Enzalutamideis predicted to moderately decrease the
exposure toapixaban. Use with caution or avoid.rStudy
▶Enzalutamidemoderately decreases the exposure to
apremilast. Avoid.rStudy
▶Enzalutamideis predicted to markedly decrease the exposure
toaprepitant. Avoid.oStudy
▶Enzalutamideis predicted to moderately decrease the
exposure toaripiprazole. Adjustaripiprazoledose,p. 249.
oStudy
▶Enzalutamideis predicted to decrease the exposure toaxitinib.
Avoid or adjust dose.oStudy
▶Enzalutamidedecreases the exposure tobedaquiline. Avoid.
rStudy
▶Enzalutamideslightly decreases the exposure tobortezomib.
Avoid.rStudy
▶Enzalutamideaffects the exposure tobosentan. Avoid.r
Study
▶Enzalutamideis predicted to very markedly decrease the
exposure tobosutinib. Avoid.rStudy916 Eliglustat—Enzalutamide BNFC 2018 – 2019
Interactions|Appendix 1A1